Dedao Wang

Key Laboratory Of Carcinogenesis And Translational Research
Beijing, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

EZH2 inhibitor SHR2554 enhances the anti-tumor efficacy of HDAC inhibitor Chidamide through STAT1 in T-cell lymphoma.

EZH2 inhibitor SHR2554 enhances the anti-tumor efficacy of HDAC inhibitor Chidamide through STAT1 in T-cell lymphoma.

Journal: Cell death & disease

Published: January 04, 2025

Interleukin-2-inducible T-cell kinase inhibition to block NF-κB signaling exerts anti-tumor effects and enhances chemotherapy in NK/T-cell lymphoma.

Interleukin-2-inducible T-cell kinase inhibition to block NF-κB signaling exerts anti-tumor effects and enhances chemotherapy in NK/T-cell lymphoma.

Journal: Cancer letters

Published: June 07, 2024

PI3K inhibitor idelalisib enhances the anti-tumor effects of CDK4/6 inhibitor palbociclib via PLK1 in B-cell lymphoma.

PI3K inhibitor idelalisib enhances the anti-tumor effects of CDK4/6 inhibitor palbociclib via PLK1 in B-cell lymphoma.

Journal: Cancer letters

Published: February 27, 2024

Management and clinical outcomes of follicular lymphoma across continuous lines of treatments: a retrospective analysis in China.

Management and clinical outcomes of follicular lymphoma across continuous lines of treatments: a retrospective analysis in China.

Journal: Frontiers in oncology

Published: July 21, 2023

Ibrutinib combined with low-dose histone deacetylases inhibitor chidamide synergistically enhances the anti-tumor effect in B-cell lymphoma.

Ibrutinib combined with low-dose histone deacetylases inhibitor chidamide synergistically enhances the anti-tumor effect in B-cell lymphoma.

Journal: Hematological oncology

Published: June 24, 2022

Clinical implications of circulating tumor DNA in predicting the outcome of diffuse large B cell lymphoma patients receiving first-line therapy.

Clinical implications of circulating tumor DNA in predicting the outcome of diffuse large B cell lymphoma patients receiving first-line therapy.

Journal: BMC medicine

Published: May 15, 2022

Survival and prognostic analysis of T-cell lymphoblastic lymphoma patients treated with dose-adjusted BFM-90 regimen.

Survival and prognostic analysis of T-cell lymphoblastic lymphoma patients treated with dose-adjusted BFM-90 regimen.

Journal: Aging

Published: January 27, 2022

Anti-CD47 immunotherapy in combination with BCL-2 inhibitor to enhance anti-tumor activity in B-cell lymphoma.

Anti-CD47 immunotherapy in combination with BCL-2 inhibitor to enhance anti-tumor activity in B-cell lymphoma.

Journal: Hematological oncology

Published: January 03, 2022

Water-assisted and protein-initiated fast and controlled ring-opening polymerization of proline N-carboxyanhydride.

Water-assisted and protein-initiated fast and controlled ring-opening polymerization of proline N-carboxyanhydride.

Journal: National science review

Published: October 15, 2021

Comparison analysis of first-line asparaginase- versus non-asparaginase-based regimens for early-stage extranodal NK/T-cell lymphoma.

Comparison analysis of first-line asparaginase- versus non-asparaginase-based regimens for early-stage extranodal NK/T-cell lymphoma.

Journal: Annals of hematology

Published: August 24, 2021

The Synergistic Anti-Tumor Activity of EZH2 Inhibitor SHR2554 and HDAC Inhibitor Chidamide through ORC1 Reduction of DNA Replication Process in Diffuse Large B Cell Lymphoma.

The Synergistic Anti-Tumor Activity of EZH2 Inhibitor SHR2554 and HDAC Inhibitor Chidamide through ORC1 Reduction of DNA Replication Process in Diffuse Large B Cell Lymphoma.

Journal: Cancers

Published: May 13, 2021

Addition of BTK inhibitor orelabrutinib to rituximab improved anti-tumor effects in B cell lymphoma.

Addition of BTK inhibitor orelabrutinib to rituximab improved anti-tumor effects in B cell lymphoma.

Journal: Molecular therapy oncolytics

Published: December 13, 2020

Showing 1-12 of 13

Last Updated: 09/26/2026